Related Experiment Video

Updated: Jun 14, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes

Danilo Verge1, Ximena López

  • 1Novo Nordisk, Medical Department, E-28033 Madrid, Spain. dver@novonordisk.com

Current Diabetes Reviews
|April 13, 2010
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose control in type 2 diabetes. These therapies also show promise in reducing cardiovascular risk factors, offering benefits beyond glycemic management.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) significantly increases cardiovascular disease (CVD) risk and mortality.
  • Many current T2D treatments do not effectively reduce CVD risk and may exacerbate risk factors.
  • Glucagon-like peptide-1 (GLP-1) receptor agonists represent a novel class of incretin-based therapies for T2D management.

Purpose of the Study:

  • To evaluate the role of GLP-1 receptor agonists in managing T2D.
  • To assess the impact of GLP-1 receptor agonists on cardiovascular risk factors.
  • To explore the potential cardioprotective mechanisms of GLP-1 and its agonists.

Main Methods:

  • Review of recent clinical trials and data on GLP-1 receptor agonists (liraglutide, exenatide).
  • Analysis of effects on glycemic control, weight, blood pressure, and lipid profiles.
  • Examination of studies investigating direct vascular and myocardial effects of GLP-1.

Main Results:

  • GLP-1 receptor agonists improve glycemic control via glucose-dependent insulin secretion and glucagon suppression.
  • Liraglutide and exenatide demonstrate significant weight loss and systolic blood pressure reduction.
  • Liraglutide positively impacts lipid profiles and cardiovascular biomarkers; GLP-1 shows direct vasodilator and cardiac function benefits.

Conclusions:

  • GLP-1 receptor agonists offer advantages in T2D treatment by improving glycemic control and addressing cardiovascular risk factors often unmet by standard therapies.
  • These agents show potential for cardiovascular risk reduction, with ongoing outcome studies to confirm clinical benefits.
  • The direct vascular and cardiac effects of GLP-1 suggest a broader therapeutic role in cardiovascular health.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...